News for Larimar Therapeutics, Inc. (LRMR)

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Larimar Therapeutics, Inc. (NASDAQ:LRMR) was one of the stocks that was covered in that article.

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Larimar Therapeutics, Inc. (NASDAQ:LRMR) was one of the stocks that was covered in that article. Wall Street analysts believe LRMR has a 957% upside potential over the next 12 months. Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a biotechnology company focused on developing innovative […]

Larimar Therapeutics (LRMR) is making significant strides in its clinical development program for nomlabofusp, aiming to deliver a groundbreaking treatment for

FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support o

Larimar stock is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market sentiment. Read why LRMR stock is a hold.

FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate en

**media[574526]**

Discover Larimar Therapeutics' Q4 2024 earnings report: GAAP EPS of -$0.45, $183.5M in cash reserves, and a strong cash runway extending into Q2 2026.

BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) ( LRMR), a clinical-stage biotechnology company focused on developin

**media[556073]**

Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate for Friedreich’s ataxia.

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) ru

**media[522913]**

**media[511560]**

Positive data from Larimar Therapeutics, Inc.'s phase 2 study on nomlabofusp for Friedreich's Ataxia suggests growth in the global market. Click for my LRMR update.

U.S. stocks traded mostly higher midway through trading, with the S&P 500 gaining around 0.4% on Monday. The Dow traded down 0.08% to 43,794.43 while the NASDA...

Larimar Therapeutics stock plunges on clinical study concerns

**media[493320]**